AUPH - Aurinia Pharmaceuticals Offers Good Entry Opportunity Before Next PDUFA For Voclosporin

• Aurinia Pharmaceuticals has one of the most important milestones in its history in a few weeks.
• Next January 22, 2021 is the PDUFA where the FDA will decide the approval of the candidate drug Voclosporin.
• Voclosporin approval by the FDA is almost assured thanks to the very good phase III trial data presented last December 2019.
• Estimates of the potential revenues that Voclosporin could generate worldwide once approved range from $1.5B to $3B per year.

For further details see: